A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA. Jodele, S; Dandoy, CE; Aguayo-Hiraldo, P; Lane, A; Teusink-Cross, A; Sabulski, A; Mizuno, K; Laskin, BL; Freedman, J; Davies, SM. Blood. 2024; 143:1112-1123.

Adopting Model-Informed Precision-Dosing for Eculizumab in Transplant Associated-Thrombotic Microangiopathy to Gene Therapies. Jodele, S; Mizuno, K; Sabulski, A; Vinks, AA. Clinical Pharmacology and Therapeutics. 2023; 114:511-514.

Model-Informed Precision Dosing Guidance of Ethosuximide Developed from a Randomized Controlled Clinical Trial of Childhood Absence Epilepsy. Mizuno, K; Capparelli, EV; Fukuda, T; Dong, M; Adamson, PC; Blumer, JL; Cnaan, A; Clark, PO; Reed, MD; Shinnar, S; Vinks, AA; Glauser, TA. Clinical Pharmacology and Therapeutics. 2023; 114:459-469.

Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines. Yi, JS; Perla, S; Huang, Y; Mizuno, K; Giordano, FJ; Vinks, AA; Bennett, AM. Cardiovascular Drugs and Therapy. 2022; 36:589-604.

Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Mizuno, K; Dandoy, CE; Teusink-Cross, A; Davies, SM; Vinks, AA; Jodele, S. Blood Advances. 2022; 6:1454-1463.

187 Eculizumab Precision Dosing Algorithm for TA-TMA in Children and Young Adults Undergoing Stem Cell Transplant. Mizuno, K; Dandoy, CE; Teusink-Cross, A; Davies, SM; Vinks, A; Jodele, S. Transplantation and Cellular Therapy. 2022; 28:s154-s155.

Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders. Chandra, S; Mizuno, K; Zhao, J; Davies, SM; Marsh, RA; Fukuda, T; Setchell, KD R; Vinks, AA; Mehta, PA. British Journal of Clinical Pharmacology. 2022; 88:115-127.

Paperspray Ionization Mass Spectrometry as a Tool for Predicting Real-Time Optimized Dosing of the Chemotherapeutic Drug Melphalan. Zhao, J; Sharat, C; Mehta, PA; Mizuno, K; Vinks, AA; Setchell, KD R. The journal of applied laboratory medicine. 2021; 6:625-636.

Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Jodele, S; Dandoy, CE; Lane, A; Laskin, BL; Laskin, B; Teusink-Cross, A; Myers, KC; Wallace, G; Nelson, A; Nelson, AS; Bleesing, J; Bleesing, JJ; Chima, RS; Chima, R; Benoit, SW; Benoit, S; Mizuno, K; Warren, M; Davies, SM. Blood. 2020; 135:1049-1057.

Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up. Saida, K; Fukuda, T; Mizuno, K; Ogura, M; Kamei, K; Ito, S. Frontiers in Pediatrics. 2019; 7:519.